Label Changes for:
Lumizyme (alglucosidase alfa)
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
6 ADVERSE REACTIONS
6.3 Postmarketing Experience...section updated
- abdominal pain, nephrotic syndrome and proteinuria, as observed events to the package insert